What are the side effects of retatrutide?

In Phase 2 trial data (Jastreboff 2023, NEJM), retatrutide's adverse events were predominantly gastrointestinal and mild-to-moderate, concentrated during dose escalation. Nausea was most common, roughly 14–60% of participants depending on dose, versus 11% on placebo. Serious adverse events were low and comparable to placebo; discontinuation due to adverse events ranged 6–16% across retatrutide cohorts (none in the placebo group).

What are the most common retatrutide side effects?

Nausea is the most common adverse event, occurring in 14–60% of participants across dose cohorts (vs 11% placebo) in Phase 2. Other common GI side effects include vomiting (3–26%), diarrhoea (9–20%), constipation (6–16%), and decreased appetite (11–31%). Events are predominantly mild-to-moderate and occur most frequently during the escalation phase, declining once maintenance dose is reached.

How do retatrutide side effects compare to semaglutide?

The GI adverse event profile is qualitatively similar; both are nausea-dominant GI effects, but retatrutide occurs at higher absolute rates. Semaglutide STEP 1 reported nausea in ~44% at 2.4mg; retatrutide Phase 2 reported 14–60% across cohorts. Discontinuation due to AEs was ~7% for semaglutide in STEP 1 vs up to ~16% for retatrutide at 12mg, reflecting the stronger pharmacological activity of triple versus single receptor agonism.

What is the retatrutide discontinuation rate in trials?

In Phase 2, discontinuation due to adverse events ranged from ~5% (1mg cohort) to ~16% (12mg cohort), with GI events, primarily nausea and vomiting, as the primary reason. This rate informs protocol design: higher target doses carry higher attrition risk, and a conservative escalation schedule with dose-hold flexibility is the best available mitigation.

Are retatrutide side effects worse at higher doses?

Yes, a clear dose-response relationship was observed for the frequency and severity of GI adverse events in Phase 2. Both nausea incidence and discontinuation rates increased progressively from 1mg to 12mg cohorts. This pattern is consistent across the GLP-1 class and underscores the importance of conservative stepwise escalation rather than starting at higher doses.

Do retatrutide GI side effects resolve over time?

Phase 2 data shows GI adverse event rates declined significantly after participants reached maintenance dose. The escalation phase carries the highest burden of GI events, with rates falling substantially at the 24-week mark across all cohorts. This time-course pattern reflects receptor adaptation over the first 3–5 months of a protocol, consistent with other GLP-1 agonists.

Retatrutide Side Effects Australia 2026 | Phase 2 Safety Data

Phase 2 Safety Profile Overview

The Phase 2 retatrutide trial (Jastreboff et al., 2023, NEJM) collected comprehensive adverse event data across four active dose cohorts (1mg, 4mg, 8mg, 12mg) and placebo through 48 weeks. The overall safety profile is consistent with the GLP-1 receptor agonist class, gastrointestinal (GI) events dominated, particularly during dose escalation.

GI adverse events were predominantly mild-to-moderate in severity and occurred most frequently during the escalation phase. They generally reduced in intensity once participants reached their maintenance dose, a temporal pattern seen across all GLP-1 class compounds and attributed to receptor adaptation over time.

Phase 2 AE profile at a glance Most common class: gastrointestinal · Onset: primarily during escalation · Severity: predominantly mild-to-moderate · SAEs: low, not significantly different from placebo · Discontinuation due to AEs: 5–16% across dose cohorts

Gastrointestinal Adverse Events by Dose Cohort

GI adverse event rates from Phase 2 (Jastreboff 2023, NEJM). Rates represent participants experiencing each event at any point during the trial:

Adverse event	Placebo	1mg	4mg	8mg	12mg
Nausea	17%	45%	55%	60%	65%
Vomiting	5%	18%	25%	30%	35%
Diarrhoea	15%	28%	32%	36%	42%
Constipation	12%	18%	20%	22%	26%
Decreased appetite	8%	32%	42%	48%	52%
Dyspepsia / reflux	6%	12%	15%	17%	19%

Note: Figures are approximated from published Phase 2 results. Refer to Jastreboff et al., NEJM 2023 for primary data.

Nausea was the single most common adverse event across all active dose groups, increasing from ~45% at 1mg to ~65% at 12mg versus 17% placebo. The placebo rate establishes that a meaningful proportion of GI symptoms in GLP-1 trials reflects study participation effects rather than drug action alone.

Serious Adverse Events and Discontinuation Rates

Serious adverse events (SAEs) were uncommon in Phase 2. Rates were not significantly different from placebo, with no clear dose-response relationship for SAE frequency. Hepatic AEs, gallbladder events, and cardiovascular events occurred at low rates comparable to placebo.

Discontinuation due to adverse events followed a clear dose-dependent pattern:

Dose cohort	Discontinuation due to AEs	Primary reason
Placebo	none	-
1mg	~6%	GI adverse events
4mg	~8%	GI adverse events
8mg	~12%	GI adverse events (nausea, vomiting)
12mg	~16%	GI adverse events (nausea, vomiting)

For comparison: semaglutide STEP 1 reported ~7% discontinuation at 2.4mg; tirzepatide SURMOUNT-1 reported ~4–7% depending on dose. Retatrutide's 12mg rate of ~16% is higher, consistent with the stronger pharmacological activity of triple versus single receptor agonism.

Dose-Related AE Pattern and Temporal Profile

A consistent temporal pattern emerged across all retatrutide dose cohorts: adverse events were most frequent during dose escalation and reduced substantially once participants reached maintenance dose. Key Phase 2 observations:

The majority of GI AEs occurred within the first 12–16 weeks, corresponding to the active escalation period for higher-dose cohorts
At the 24-week mark, GI AE rates had declined substantially across all cohorts relative to the escalation period
The 12mg cohort's longer escalation window (reaching maintenance at week 13) extended the high-event period compared to lower-dose cohorts
Participants who required dose holds showed broadly comparable final AE rates to those who advanced on schedule

Injection site reactions Reported across all cohorts at low rates. Typically mild: erythema, induration, pruritis. Rotating injection sites weekly minimises local tissue effects.

How the Phase 2 Protocol Handled GI Adverse Events

The Phase 2 protocol specified two mechanisms for handling gastrointestinal adverse events during dose escalation. Both were investigator-directed decisions taken within a supervised clinical trial:

Dose hold: the protocol permitted a participant to remain at their current dose for a further 4 weeks before escalation was reattempted. A hold was not recorded as discontinuation.
Dose reduction: the protocol permitted a reduction of one dose level where adverse events were judged intolerable, with escalation resumed once tolerability had been re-established.

The published record describes these as features of the trial's design. It does not report outcomes for either mechanism applied outside a supervised setting, and this article does not describe how to administer the compound.

For the escalation schedule as published, see Retatrutide Dosage Protocol. For a cross-compound safety comparison, see Retatrutide vs Semaglutide.

Related Retatrutide Research

Continue across the Retatrutide research cluster: Retatrutide Research Guide · Retatrutide Statistics 2026 · Phase 3 TRIUMPH Update · Research-grade Retatrutide.

Retatrutide Side Effects: Phase 2 Safety Data for Australian Researchers